Related Experiment Video
Updated: Jul 8, 2026
08:34
Isolation of Atrial Myocytes from Adult Mice
Published on: July 25, 2019
Circulating natriuretic peptide levels in acute heart failure
1Cardiac Care Unit and Heart Failure Program, San Diego Veterans Affairs Medical Center, San Diego, California, USA.
Reviews in Cardiovascular Medicine
|January 16, 2008
Summary
Natriuretic peptide (NP) levels are accepted biomarkers for diagnosing dyspnea. These NP levels decrease during hospitalization, suggesting their future use in guiding outpatient treatment.
Area of Science:
- Biochemistry
- Cardiology
- Clinical Diagnostics
Background:
- Natriuretic peptides (NPs) are widely recognized biomarkers.
- NPs are valuable for ruling in or out conditions in patients with dyspnea.
- Altered forms of B-type natriuretic peptide (BNP), such as pro-BNP, can be present in hospitals.
Purpose of the Study:
- To review the role of natriuretic peptide levels in clinical practice.
- To discuss the significance of NP levels in patients presenting with dyspnea.
- To explore the potential future applications of NP monitoring.
Main Methods:
- Review of current literature on natriuretic peptide biomarkers.
- Analysis of NP level dynamics during hospitalization.
- Discussion of NP levels as indicators for therapeutic adjustments.
Main Results:
- NP levels are established as effective biomarkers for dyspnea assessment.
- A decrease in NP levels is observed during patient decongestion in hospitals.
- Altered NP forms, including pro-BNP, may be present and relevant.
Conclusions:
- Natriuretic peptide levels are crucial for diagnosing dyspnea.
- The observed drop in NP levels during hospitalization indicates treatment effectiveness.
- Future applications may involve using NP levels to guide outpatient therapy titration.
Related Concept Videos
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:17Hormonal Regulation of Blood Pressure
Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...
01:30Heart Failure VII: Nursing Interventions
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...